April 25, 2017: Less than 10 days after OncoMed announced its mid-stage combination lung cancer treatment failed to meet endpoints, the company has slashed half its workforce in an effort to focus its finances on three clinical-stage programs.
April 25, 2017: Only a month or so after making an public relations gaff in pricing its steroid for DMD for $89,000, Marathon Pharma apparently has plans to close its doors. On February 10, Marathon announced that the FDA had approved Emflaza (deflazacort) to treat DMD.
April 25, 2017: Alzheimer’s disease remains an elusive target for drug manufacturers. Approximately 99 percent of drug trials for the disease have failed, including high-profile failures like Pfizer and J&J's bapineuzumab and Eli Lilly’s solanezumab.
April 25, 2017: Germany-based Fresenius Kabi slapped down $4.3B to acquire Illinois-based Akorn Pharma and a larger toehold in the U.S. With the deal, Fresenius gained the generic drugmaker, which it said will complement its existing business.